17 days before the patent expires, pharmaceutical company lowers the price of Rybelsus and offers free dose of Wegovy
Novo Nordisk has announced a significant price reduction for its medications Rybelsus and Wegovy, ahead of the expiration of the patent for Ozempic.
End of the semaglutide patent in 2026 intensifies market disputes among China, India, USA, Canada, and Brazil
The expiration of semaglutide's patent in 2026 is expected to ignite competition among major global markets including China, India, the USA, Canada, and Brazil, particularly in the lucrative obesity treatment sector.
Brazilian pharmaceutical companies seek Indian technology for weight loss pen manufacturing
Brazilian pharmaceutical firms Biomm and Amoveri are pursuing Indian technology agreements to produce weight loss pens ahead of the patent expiration for Ozempic in 2026.
Pharmaceutical company Dr. Reddy's prepares to launch a cheap generic Ozempic in India in March
Indian pharmaceutical company Dr. Reddy’s Laboratories is set to launch a generic version of the diabetes drug Ozempic, named Obeda, in March 2026 following the expiration of the semaglutide patent.
End of Ozempic patent could reduce price by up to 35%, says laboratory wanting to make generic
The expiration of the semaglutide patent in March is expected to lead to a price reduction of up to 35% for Ozempic, according to pharmaceutical company EMS, which is interested in producing a generic version.
A generic Ozempic for 15 euros per month or how to revolutionize the obesity drug market
The expiration of Novo Nordisk's patent in some countries pressures the Danish pharmaceutical company as its diabetes injection Ozempic becomes synonymous with weight loss globally.